We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ovoca Bio Plc | LSE:OVB | London | Ordinary Share | IE00B4XVDC01 | EUR0.125 (CDI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.025 | -3.33% | 0.725 | 239,030 | 10:17:31 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.60 | 0.85 | 0.75 | 0.70 | 0.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | EUR 1.46M | EUR -5.61M | EUR -0.0688 | -0.10 | 587.26k |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 14:49:59 | O | 7,497 | 0.625 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/1/2024 | 07:00 | UKREG | Ovoca Bio PLC Holding(s) in Company |
| 01/12/2023 | 12:00 | UKREG | Ovoca Bio PLC Result of AGM |
| 07/11/2023 | 09:15 | UKREG | Ovoca Bio PLC Notice of AGM |
| 28/9/2023 | 14:41 | ALNC |  EARNINGS: Ovoca "to adapt" after study let-down, Kelso NAV rises |
| 28/9/2023 | 07:00 | UKREG | Ovoca Bio PLC Interim Results |
| 31/8/2023 | 12:08 | ALNC | Ovoca Bio shares dive following disappointing Orenetide study results |
| 31/8/2023 | 07:00 | UKREG | Ovoca Bio PLC Summary Results of Phase II Study for Orenetide |
| 30/6/2023 | 17:26 | ALNC | EARNINGS SUMMARY: Powerhouse loss widens hugely, DCI Advisors narrows |
| 30/6/2023 | 07:00 | UKREG | Ovoca Bio PLC Annual Financial Report |
| 12/6/2023 | 09:01 | ALNC | Ovoca Bio shares down as study delayed due to staffing issues |
Ovoca Bio (OVB) Share Charts1 Year Ovoca Bio Chart |
|
1 Month Ovoca Bio Chart |
Intraday Ovoca Bio Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/4/2024 | 15:15 | Ovoca Bio...market cap Ј8.8, stake in Polymetal worth Ј14.8 | 673 |
| 05/12/2023 | 02:13 | Viagra for women | 755 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-17 13:50:00 | 0.63 | 7,497 | 46.86 | O |
| 2024-04-17 10:13:35 | 0.81 | 11,606 | 94.00 | O |
| 2024-04-17 09:17:21 | 0.77 | 31,042 | 239.02 | O |
| 2024-04-17 07:01:12 | 0.62 | 188,885 | 1,171.09 | O |
| Top Posts |
|---|
Posted at 17/4/2024 09:20 by Ovoca Bio Daily Update Ovoca Bio Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker OVB. The last closing price for Ovoca Bio was 0.75p.Ovoca Bio currently has 81,563,806 shares in issue. The market capitalisation of Ovoca Bio is £587,259. Ovoca Bio has a price to earnings ratio (PE ratio) of -0.10. This morning OVB shares opened at 0.75p |
Posted at 01/3/2024 14:32 by mdi hTtps://www.proactiv |
Posted at 02/2/2024 11:10 by jimtech As I had difficulty asking questions at the OVB AGM I sent some later by email.Here are their responses which might be of interest. Bear in mind I received their email below on 4th December so it is a couple of months old: [JT 2] Clearly the recent Australian / New Zealand Orenetide trial results were extremely disappointing. It would seem to me that there has either been a flaw in previous trials or in this recent one. Which one is it? [OVB] We strongly disagree that the disappointing results of a recent study mean that there is a flaw in this or the previous studies. Clinical studies are very complex scientific process with risks and uncertain outcome, despite any previous results. This was disclosed in Ovoca’s Re-Admission Document for the Proposed Acquisition of IVIX (Part 2 “Risk factors”, “RISKS RELATING TO THE ENLARGED GROUP AND THE SECTOR IN WHICH IT OPERATES” at p. 19-20): “…Clinic Unfortunately, it seems that this scientific risk has been realized. [JT 3] Who oversaw the previous Russian Orenetide (BP-101) trials? Was it the management of IVIX? [OVB] The previous Russian Orenetide (BP-101) trials were administrated by one of the leading Russian Contract Research Organizations (CRO) – OCT Clinical Trials. Trials Sponsor oversight (which is mandatory according to ICH GCP standard on clinical trials) was done by the management of IVIX. This is public information, but disclosed in the Russian clinical trials registry (however we have checked – automated page translation into English is available in the Chrome browser, and we assume it should be available in other major browsers). Also, public information is available in the Clinicaltrials.gov registry: hxxps://www.clinical [JT 4] Is there any future at all for Orenentide? [OVB] For the moment we are not ready to make any conclusions – study report is still in process, and additional internal assessments are ongoing. The Company will determine the appropriate future strategy regarding the development of Orenetide, including whether the Company can and should continue with its development of this product. [JT 5] What is the future strategy for Ovoca Bio now? [OVB] Again, we are assessing the Orenetide trial results and any implications this may have for the wider strategy of the Company, including a number of potential strategies. We will keep shareholders informed on any developments as and when appropriate. Please keep in mind that while answering to this question we are limited by AIM rules on disclosure of material and insider information, so our reply may not contain any significant comments / material updates beyond anything that already has been published via RNS. |
Posted at 25/10/2023 20:02 by dave4545 Somebody got a excellent price today 1.2p or less. |
Posted at 31/8/2023 19:09 by dave4545 So market cap has closed exactly the same as cash in RNS end of July.Given there is always a option to turn into a shell and move in a new direction I feel I might as well hold especially as current stake is only worth less than £2k. Remember when ITS collapsed then turned into a shell and 25 bagged from their low. Lets see what Ovb decide to do |
Posted at 31/8/2023 17:39 by andymunchkin Mcrudden20 Dec '19 - 15:27 - 38 of 6520 0 0 Solid company very surprised at those sells. Especially as it takes ages to even get a buy quote. Nt nt nt every time I tried this week, you can lead a horse to water as they say. Gla ------ Mcrudden23 Dec '19 - 12:15 - 43 of 652 0 0 0 Spot on Dave anyone selling this morning was chasing a rainbow elsewhere, mms have no stock at this level like you said. Solid company big prospects just hold for 5 ------ Mcrudden3 Jan '20 - 16:14 - 54 of 652 0 0 0 So much value in this share anything at these prices is worth multiples. Just got to hold it would seem. ----- yUp |
Posted at 30/6/2023 07:19 by dave4545 "During 2022, the Company also disposed of its remaining holdings of ordinary shares of Polymetal International plc"Would have been nice to know if that was before or after the collapse in Poly price. Started 2023 with over £3 mil, they got £1 mil for sale of Russian Assets. Trial finished end of 2022, so costs should be down as we wait for results of trial. Just saying it's still got quite a bit of cash backing v market cap of just under £5 mil. It also means there still could be other options worse case if the trial data was poor but hopefully not. |
Posted at 10/5/2023 10:34 by dave4545 Good job OVB sold most of their poly shares shame they did not have the sense to sell the lot when they were £20 a share.And still we wait for trial results. I'm trying to be logical here but if they were no good/bad then they would have told us by now but then again I suppose that could apply if they were positive |
Posted at 09/2/2023 13:30 by dave4545 Slight life on L2 now 2 bid and buy price increasing on small buying |
Posted at 04/8/2021 18:05 by hedgehog 100 Last summer was a period of excellent OVB share price performance, starting with its final results, as investors anticipated Russian marketing approval, and the same should apply this time too.Ultimately approval last year was temporarily knocked back, but only for minor procedural 'box-ticking' stuff. Crucially, there were no concerns raised about the drug's effectiveness or safety, which are the two key criteria: 02/10/2020 07:00 UK Regulatory (RNS & others) Ovoca Bio PLC Update re Russian Marketing Authorisation " ... Ovoca has been informed that the Minzdrav has not granted the MA to BP-101 following the identification of certain issues relating to the chemistry, manufacturing and controls (CMC) and labelling sections of the MA submission dossier. The Company notes that no issues were highlighted by the Minzdrav regarding the safety or efficacy of BP-101 in the acquired generalized form of HSDD, which has been established by clinical data from two Phase 1 studies, a Phase 2a study and the pivotal Phase 3 study completed in 2019, all as conducted in the Russian Federation. ..." So approval this time round looks like a formality, and it could be as early as October. |
Posted at 26/6/2021 20:48 by hedgehog 100 24/06/2021 07:00 UKREG Ovoca Bio PLC Annual Report and Notice of AGMWell, OVB's finals are out, as well as a new presentation on the company's website, and it all makes for very arousing reading! The news that OVB's drug can also help with female orgasms is great news, and it underlines how OVB could have a 'licence to print money' here ... or should I say a 'licence to make women runny'!! Last summer was a period of excellent OVB share price performance, starting with its final results, as investors anticipated Russian marketing approval, and the same should apply this time too. Ultimately approval last year was temporarily knocked back, but only for minor procedural 'box-ticking' stuff. Crucially, there were no concerns raised about the drug's effectiveness or safety, which are the two key criteria: 02/10/2020 07:00 UK Regulatory (RNS & others) Ovoca Bio PLC Update re Russian Marketing Authorisation " ... Ovoca has been informed that the Minzdrav has not granted the MA to BP-101 following the identification of certain issues relating to the chemistry, manufacturing and controls (CMC) and labelling sections of the MA submission dossier. The Company notes that no issues were highlighted by the Minzdrav regarding the safety or efficacy of BP-101 in the acquired generalized form of HSDD, which has been established by clinical data from two Phase 1 studies, a Phase 2a study and the pivotal Phase 3 study completed in 2019, all as conducted in the Russian Federation. ..." So approval this time round looks like a formality, and it could be as early as October. That should give an immediate big boost to the s.p., and should be followed by news on this: "Discussions are progressing with a leading local candidate that can both manufacture and distribute BP-101." Sales should then commence in Russia, the world's largest country, providing great cashflow to complement OVB's already excellent balance sheet. And we also have the results of the Australia and New Zealand trials to look forward to, probably by the end of the year, a major step on the road to opening up other markets, including Europe and the US. It's quite incredible that you can buy such a well-funded and proven biotech, with such massive potential, for a sub £10M. market cap. A market cap. of £100s of millions looks very possible longer-term if the company delivers upon its potential. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
